

Sabrina Rossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1846249/publications.pdf>

Version: 2024-02-01

22
papers

517
citations

758635

12
h-index

713013

21
g-index

22
all docs

22
docs citations

22
times ranked

884
citing authors

#	ARTICLE	IF	CITATIONS
1	Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. <i>Current Problems in Cancer</i> , 2022, 46, 100787.	1.0	5
2	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1251.	1.0	21
3	Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020, 21, 28-36.	1.1	5
4	Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 821-826.	2.8	73
5	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. <i>Cancers</i> , 2020, 12, 1373.	1.7	24
6	Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2020, 12, 715-724.	1.0	13
7	¹⁸ F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. <i>Current Radiopharmaceuticals</i> , 2020, 13, 228-237.	0.3	17
8	Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 487.	1.7	29
9	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102894.	2.0	27
10	The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1235-1243.	1.2	39
11	Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience. <i>Immunotherapy</i> , 2019, 11, 945-952.	1.0	2
12	Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1537-1545.	2.0	10
13	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3775-3782.	1.1	10
14	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. <i>Immunotherapy</i> , 2018, 10, 797-805.	1.0	20
15	Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?. <i>Clinical Colorectal Cancer</i> , 2017, 16, 264-274.	1.0	94
16	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 59.	1.3	3
17	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 55-63.	1.6	22
18	Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. <i>Future Oncology</i> , 2016, 12, 1299-1307.	1.1	16

#	ARTICLE	IF	CITATIONS
19	ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. <i>Oncotarget</i> , 2016, 7, 35159-35168.	0.8	14
20	Are TKIs favourable for the elderly with non-small-cell lung cancer?. <i>Oncotarget</i> , 2016, 7, 46871-46877.	0.8	7
21	Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease. <i>Clinical Breast Cancer</i> , 2015, 15, 307-312.	1.1	66
22	K-RAS codon 13 mutation in advanced colorectal cancer: A single-center retrospective study investigating prognostic outcomes and treatment strategies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 633-633.	0.8	0